Hsbc Holdings PLC Incyte Corp Call Options Transaction History

Hsbc Holdings PLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2021 Feb 11, 2022	SELL	$63.34 - $74.11 $259,694 - $303,851	-4,100 Reduced 35.96%	7,300 $0
Q3 2021 Nov 12, 2021	BUY	$68.67 - $84.02 $61,803 - $75,618	900 Added 8.57%	11,400 $787,000
Q2 2021 Aug 13, 2021	SELL	$79.87 - $87.53 $143,766 - $157,554	-1,800 Reduced 14.63%	10,500 $0
Q1 2021 May 14, 2021	SELL	$76.02 - $100.5 $836,220 - $1.11 Million	-11,000 Reduced 47.21%	12,300 $0
Q4 2020 Feb 25, 2021	BUY	$80.74 - $97.7 $1.74 Million - $2.1 Million	21,500 Added 1194.44%	23,300 $0
Q4 2020 Feb 12, 2021	SELL	$80.74 - $97.7 $1.67 Million - $2.02 Million	-20,700 Reduced 92.0%	1,800 $0
Q3 2020 Nov 12, 2020	BUY	$85.07 - $109.69 $153,126 - $197,442	1,800 Added 8.7%	22,500 $2.03 Million
Q1 2020 May 15, 2020	SELL	$63.18 - $85.97 $1.18 Million - $1.6 Million	-18,600 Reduced 47.33%	20,700 $1.51 Million
Q2 2018 Aug 10, 2018	BUY	$60.85 - $83.98 $2.39 Million - $3.3 Million	39,300 New	39,300 $2.63 Million

645

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.3B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.